Merck generates strong cash flows from its portfolios, says Argus

Argus keeps a Buy rating and $125 price target on Merck, noting that the company has achieved strong top-line growth in Q2, as sales rose 7% on an operational basis. The company generates strong cash flows from its portfolio of oncology, hospital care, and antiviral products, the analyst tells investors in a research note. Merck also continues to receive regulatory approvals for additional indications for its products, including a new approval for Keytruda in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, the firm added.